Novo Nordisk A/s

This Phase 3 trial tests whether cagrilintide, a new injectable drug, helps people with overweight or obesity lose weight. About 300 adults will receive either cagrilintide or a placebo for up to 18 months, along with lifestyle counseling. The study measures weight change and wai…

This study tests whether semaglutide, a medicine already used for type 2 diabetes, can help people with NASH, a serious liver condition. About 1205 adults with NASH and liver scarring (stage 2 or 3) will receive weekly injections of semaglutide or a placebo for up to 5 years. The…

This study observes how well insulin icodec controls blood sugar in 245 people with type 1 diabetes who have never used it before. Participants take the insulin as prescribed by their doctor, and researchers track changes in HbA1c and treatment satisfaction over about 22 to 30 we…

This study tests a daily injection called concizumab in children under 12 with hemophilia A or B, with or without inhibitors. The goal is to see if it safely prevents bleeding episodes. Participants receive daily shots under the skin for at least 2 years, and the study tracks how…

This study follows 30 people with hemophilia A or B (without inhibitors) in Japan who are already using Alhemo (concizumab) as part of their routine care. Researchers will monitor side effects and how well the drug works over about 2 years per person. The goal is to see if Alhemo…

This two-year study will follow 1,250 people with obesity who are starting Wegovy (semaglutide) as part of their regular medical care. Researchers will track changes in weight, waist size, and quality of life to see how the drug performs outside of clinical trials. The goal is to…

This study tests whether a once-weekly injection of semaglutide helps children and teenagers (ages 6 to 17) with obesity or overweight lose weight. About 210 participants will receive either the drug or a placebo for up to 2.5 years, along with healthy lifestyle counseling. The m…

This study tests if a new growth hormone medicine (somapacitan) given once a week works as well as the standard daily growth hormone (Norditropin) for children who are very short due to being born small, or having Turner syndrome, Noonan syndrome, or unknown causes. About 412 chi…

This study tests a drug called concizumab, given as a daily shot under the skin, to prevent bleeding in people with hemophilia A or B who have inhibitors (antibodies that block standard treatment). About 134 participants either start concizumab right away or continue their usual …

This study tests a new once-weekly growth hormone medicine (somapacitan) against a daily one (Norditropin) in 62 children born small who remain short. The goal is to see if the weekly shot works as well and is safe. Children receive injections either once a week or once a day for…

This study tests a medicine called concizumab for people with hemophilia A or B who do not have inhibitors. The goal is to see if a daily shot under the skin can prevent bleeding episodes safely. About 156 participants, aged 12 and older, will either start concizumab right away o…

This study tests a new investigational medicine called CagriSema against an approved drug, tirzepatide, in people with type 2 diabetes whose blood sugar is not well controlled by current pills. About 1,023 adults will receive either CagriSema or tirzepatide once a week for up to …

This study tests whether a weekly injection of semaglutide can help 500 adolescents with obesity lose weight and maintain that loss for at least 3 years. All participants receive the medicine, which is injected into the stomach, thigh, or upper arm. The goal is to see if the drug…

This study tests whether a daily injection of liraglutide (3.0 mg) can help children aged 6 to 12 with obesity lose weight. Over 56 weeks, 78 children will receive either liraglutide or a placebo, along with counseling on diet and exercise. The main goal is to see how much their …

This study tests whether a weekly injection of CagriSema (a combination of two drugs) can reduce the risk of heart attacks, strokes, and other heart-related events in people with established cardiovascular disease. About 7,100 participants will receive either CagriSema or a place…

This study tests a new medicine called NNC0662-0419, given as a weekly shot, to see if it helps people with overweight or obesity lose weight safely. About 224 adults aged 18-65 with a BMI of 27 or higher will receive either the drug or a placebo. The main goals are to check for …

This Phase 3 study tests a once-weekly injection called CagriSema, which combines two drugs (cagrilintide and semaglutide), to help people with overweight or obesity lose weight. About 3,400 adults will receive either CagriSema, one of the drugs alone, or a placebo for 1.5 years,…

This study looks at how safe and effective Ozempic is for adults with type 2 diabetes when used in normal doctor visits. About 600 people in Korea will take Ozempic as their doctor prescribes, and the study lasts around 26 weeks. The main goal is to track any side effects and ser…

This study looks at whether semaglutide, a medicine for type 2 diabetes, can slow or prevent diabetic eye disease over 5 years. About 1500 adults with type 2 diabetes will receive either semaglutide or a placebo injection once a week, in addition to their usual diabetes medicatio…

This study follows 200 children in Japan with growth hormone deficiency who are taking Sogroya® (somapacitan) as part of their normal care. Researchers will monitor side effects and growth over 1 to 3 years to see how safe and effective the drug is in real-world use. Participants…

This study follows over 1,000 people with obesity in Japan who are taking Wegovy as prescribed by their doctor. Researchers will track side effects and weight changes for about 2 years to see how the drug works in everyday life, not just in a lab. The goal is to better understand…

This study tests a new medicine called cagrilintide to help people who are overweight or have obesity and type 2 diabetes lose weight. About 330 adults will receive either cagrilintide or a placebo for around 18 months. The main goals are to see how much weight they lose and how …

This study follows 200 adults in Japan with severe growth hormone deficiency who are taking Sogroya as part of their normal care. Researchers will monitor side effects and changes in body composition over 2 to 5 years. Participants will also fill out quality-of-life questionnaire…

This Phase 3 trial is testing whether a monthly injection of ziltivekimab can reduce the risk of heart attacks and strokes in 6,200 people who already have heart disease, chronic kidney disease, and signs of inflammation. Participants receive either the drug or a placebo for up t…

This early-stage trial tests a new weekly injection called NNC0194-0499, alone or with another drug (semaglutide), in 96 adults with type 1 diabetes. The goal is to see if it improves blood sugar levels compared to placebo. All participants continue their usual insulin. The study…

This study tests whether a new tablet formulation of semaglutide (oral semaglutide D) works as well as the approved version in Japanese adults with type 2 diabetes. About 264 participants will take either the new or approved tablet once daily for 27 weeks. Researchers will compar…

This study tests a new medicine called CagriSema (a mix of two drugs) for helping people with obesity lose weight. About 400 adults with a BMI of 35 or higher will receive either CagriSema or a placebo for 2 years, then some will continue or slowly stop the medicine for another y…

This study follows about 60 males with hemophilia A who are already using Esperoct to prevent bleeds. Researchers will track side effects and how well the medicine controls bleeding over 5-7 years. Participants continue their normal treatment and clinic visits, with no extra proc…

This study will follow 500 Korean adults with obesity who are starting Wegovy (semaglutide) as part of their normal care. Researchers will track how much weight they lose and any side effects over about 52 weeks. The goal is to see how effective and safe the drug is in real-world…

This Phase 3 study tests CagriSema, a weekly injection combining two drugs (cagrilintide and semaglutide), for weight loss and long-term weight maintenance in 609 adults with obesity. Participants are randomly assigned to receive either CagriSema or a placebo for over 3 years. Th…

This study tests the long-term safety of an experimental drug called NNC6019-0001 in people with transthyretin amyloid cardiomyopathy, a rare heart disease that can lead to heart failure. All 80 participants have already completed an earlier study and will receive the drug every …

This study tests a new growth hormone medicine called somapacitan, given once a week, in 47 children who are very short due to being born small for gestational age, or having Turner syndrome, Noonan syndrome, or idiopathic short stature. The main goal is to see if it is safe and …

This study tests community-based programs in six countries to help children ages 6-13 eat healthier and be more active. The goal is to prevent obesity and improve quality of life in disadvantaged urban communities. Researchers will track changes in body mass index and health-rela…

This early-stage study tests a new medicine for people who are overweight or have obesity. The main goal is to check if the medicine is safe and how the body processes it. About 63 participants will receive either the study drug or a placebo as an injection under the skin. The me…

This study tests whether a new medicine called CagriSema can reduce nerve pain in people with type 2 diabetes. About 142 adults with painful diabetic neuropathy will receive either CagriSema or a placebo for around 10 months. The main goal is to see if the drug lowers weekly pain…

This study examines health data from about 800,000 Korean adults to see how often conditions like obesity, type 2 diabetes, heart disease, chronic kidney disease, and fatty liver occur together. Researchers will analyze national survey and insurance records from 2013 to 2023. No …

This study tracks the safety and effectiveness of the drug Alhemo (concizumab) in 23 people with hemophilia A or B in Japan. Participants receive the drug as part of their normal care, and researchers will monitor side effects for about 2 years. The goal is to see how well Alhemo…

This study follows 400 adults with growth hormone deficiency who are already taking Sogroya (somapacitan) as part of their normal care. Researchers will monitor side effects and effectiveness over 5 to 10 years. Participants will also fill out questionnaires about their well-bein…

This study follows 60 males with haemophilia B who are already using the drug Refixia (nonacog beta pegol) to prevent bleeding. Researchers will collect information on side effects, bleeding episodes, and quality of life over 4 to 9 years. No new treatment is given—participants c…

This study looks at health records of about 1,100 women who took Wegovy during pregnancy and compares them to those who did not. The goal is to see if the drug increases risks for birth defects or other problems in babies. Researchers will use insurance claims data to track outco…

This large study looks back at medical records of 100,000 Chinese patients with type 2 diabetes to compare heart and kidney outcomes between those taking Ozempic and those on other diabetes drugs. Researchers will track major heart problems, strokes, and kidney events. The goal i…

This 10-year observational study will follow 500 children with growth hormone deficiency who are receiving the once-weekly injection somapacitan as part of their routine care. Researchers will track side effects, medication errors, and new cases of cancer or type 2 diabetes. The …

This study follows pregnant women who took Wegovy for obesity or overweight to see if it affects the baby's health. Researchers compare these women to similar pregnant women who did not take Wegovy. The goal is to check for birth defects and other health issues in infants during …

This study follows 96 people with moderate Parkinson's disease for up to 24 months. Participants take their usual medications, and doctors may adjust them as needed. Researchers will track motor symptoms using standard rating scales to better understand how the disease progresses…

This study collects information through online surveys from about 2,500 adults in Australia, Germany, UAE, and Spain who have been prescribed injectable semaglutide for weight management. The goal is to understand their characteristics, treatment experiences, and changes in weigh…

This study collects information from doctors and patient groups across Asia and the Pacific to better understand how haemophilia affects people in the region. No treatments or medications are given; instead, researchers will analyze data on how many people have the condition, how…

This study gathers safety information from a European registry for people with haemophilia A who are treated with turoctocog alfa pegol. Researchers will count any side effects reported to the registry that might be linked to the drug. About 50 participants are involved, and ther…

This study looks at children and teenagers with growth hormone deficiency or who were born small for their age. It tracks how closely they follow their prescribed Norditropin® treatment and whether that affects their final height. The study is observational, meaning no new treatm…

This study is a registry that will follow up to 221 children with Noonan Syndrome who are already taking or starting Norditropin® for short stature. Researchers will collect information on growth, side effects, and quality of life over time. No new treatment is being tested—the g…